Merck (MRK) Raises Quarterly Dividend 5.5% to $0.77; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as higher oil prices temper risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Reddit to join S&P 500 index on Aug. 18, shares leap
- Should you chase this mini rally in gold? Citi weighs in
Merck Announces First-Quarter 2024 Dividend
November 28, 2023 1:17 PM ESTRAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the companys common stock for the first quarter of 2024. Payment will be made on Jan. 8, 2024, to shareholders of record at the close of business on Dec. 15, 2023.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge... More
Merck Announces First-Quarter 2024 Dividend
November 28, 2023 1:17 PM ESTRAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the companys common stock for the first quarter of 2024. Payment will be made on Jan. 8, 2024, to shareholders of record at the close of business on Dec. 15, 2023.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge... More
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV
November 28, 2023 6:45 AM ESTThe 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021
Results from Phase 3 trial, STRIDE-3, to be presented at World Vaccine Congress West Coast
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-3, a Phase 3 trial evaluating V116, the companys investigational 21-valent pneumococcal conjugate vaccine specifically designed to protect adults. The trial evaluated the... More
